COCRYSTAL PHARMA, INC. Deferred Tax Assets, Tax Deferred Expense
COCRYSTAL PHARMA, INC. (COCP) had Deferred Tax Assets, Tax Deferred Expense of $550.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpense · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense $550.00K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense $666.00K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense $583.00K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense $474.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense |
|---|---|
| 2025-12-31 | $550.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $666.00K 10-K · filed 2026-03-31 |
| 2023-12-31 | $583.00K 10-K · filed 2025-03-31 |
| 2022-12-31 | $474.00K 10-K · filed 2024-03-28 |
| 2021-12-31 | $846.00K 10-K · filed 2023-03-29 |
| 2020-12-31 | $837.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |